BIOLOGICAL MARKERS OF CARDIOVASCULAR RISK IN DIABETES MELLITUS

Download full text PDF
Issue: 
4
Year: 
2017

Professor A. Berezin, MD VitaCenter Multidisciplinary Hospital, Zaporozhye, Ukraine Medical University, Zaporozhye, Ukraine

Diabetes mellitus (DM) retains its value as one of the most important cardiovascular risk factors in both the general population and patients with verified cardiovascular diseases. Moreover, the assessment of an individual risk for cardiovascular events in DM is a subject of scientific debate. The possibility of stratifying patients with DM into groups at risk for poor prognosis, by using biological markers, is considered.
Keywords: 
diabetes mellitus
biological markers
cardiovascular risk
prognosis

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. da Rocha Fernandes J., Ogurtsova K., Linnenkamp U. et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes // Diabetes Res. Clin. Pract. – 2016; 117: 48–54.
  2. Padwal R., Majumdar S., Johnson J. et al. A systematic review of drug therapy to delay or prevent type 2 diabetes // Diabetes Care. – 2005; 28: 736–44.
  3. Ingelfinger J., Rosen C. Cardiac and Renovascular Complications in Type 2 Diabetes – Is There Hope? // N. Engl. J. Med. – 2016 [Epub. ahead of print].
  4. Berezin A. Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives // Diabetes Metab. Syndr. – 2016; 10 (2 Suppl. 1): 176–83.
  5. Schernthaner G., Jarvis S., Lotan C. et al. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes // Ther. Clin. Risk. Manag. – 2017; 13: 69–79.
  6. Wurm R., Resl M., Neuhold S. et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles // Heart. – 2016. [Epub. ahead of print].
  7. Chamberlain J., Rhinehart A., Shaefer C. Jr. et al. Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes // Ann. Intern. Med. – 2016; 164 (8): 542–52.
  8. Berezin A. Cardiac biomarkers in diabetes mellitus: new dawn for risk stratification? // Diabetes Metab. Syndr.: Clin. Res. Rev. – 2016 [Epub. ahead of print]. DOI: 10.1016/j.dsx.2016.12.032.
  9. Berezin A. Biomarkers for cardiovascular risk in patients with diabetes // Heart. – 2016; 102 (24): 1939–41.
  10. Horswell R., Wascom C., Cerise F. et al. Diabetes mellitus medication assistance program: relationship of effectiveness to adherence // J. Health Care Poor Underserved. – 2008; 19 (3): 677–86.
  11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework // Clin. Pharmacol. Ther. – 2001; 69: 89–95.
  12. Saudek C., Herman W., Sacks D. et al. A new look at screening and diagnosing diabetes mellitus // J. Clin. Endocrinol. Metab. – 2008; 93: 2447–53.
  13. Berezin A. Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15 // Diabetes Metab. Syndr. – 2016; 10 (1 Suppl. 1): 154–7.
  14. van der Leeuw J., Beulens J., van Dieren S. et al. Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus // J. Am. Heart Assoc. – 2016; 5 (6). DOI: 10.1161/JAHA.115.003048.
  15. Wurm R., Resl M., Neuhold S. et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles // Heart. – 2016; 102 (19): 1544–51.
  16. Alonso N., Lupón J., Barallat J. et al. Impact of diabetes on the predictive value of heart failure biomarkers // Cardiovasc. Diabetol. – 2016; 15 (1): 151.
  17. Eggers K., Kempf T., Larsson A. et al. Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community // Clin. Chem. – 2016; 62 (3): 485–93.
  18. Adela R., Banerjee S. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective // J. Diabetes Res. – 2015; 2015: 490842.
  19. Kempf T., Wollert K. Growth differentiation factor-15: a new biomarker in cardiovascular disease // Herz. – 2009; 34 (8): 594–9.
  20. Resl M., Clodi M., Vila G. et al. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes // Heart. – 2016; 102 (24): 1963–8.